North American generics makers call for rejection of new exclusivity period for biologics
Concerned that patients who seek affordable medicines will be harmed, the Association for Accessible Medicines, along with the Canadian Pharmaceutical Association, and Mexican Association of Generic Medicines issued the following statement criticizing the announced trade understanding between the United States and Mexico to extend brand name biologic data protection to ten years:
“This provision would harm the growing biosimilar industry, which aims to provide price competition to some of the most expensive prescription drugs and allow patients to benefit from affordable medicines. The U.S., Mexico and Canada should reject these provisions, which would benefit brand name drug companies to the detriment of public health and the affordability of medical care.”
“This provision would harm the growing biosimilar industry, which aims to provide price competition to some of the most expensive prescription drugs and allow patients to benefit from affordable medicines. The U.S., Mexico and Canada should reject these provisions, which would benefit brand name drug companies to the detriment of public health and the affordability of medical care.”